newsfilter
← Latest News
PR Newswire·

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology

Illumina, Inc. (NASDAQ: ILMN) today announced that reimbursement has been granted for its FDA-approved in vitro diagnostic (IVD) TruSight™ Oncology...